Bionet

Bionet Current Assets

The Current Assets of Bionet (1784.TWO) as of Nov 2, 2026 is 125.87 M TWD. In the previous year, Current Assets was 391.86 M TWD — a change of -67.88% (lower).

Current Assets

125.87 MTWD

YoY

-67.88%

Last updated:

Current Assets of Bionet is 2025 125.87 M TWD. Current Assets of Bionet was 2024 391.86 M TWD. It decreases by -67.88% lower compared to the previous year.

The Bionet Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
345.27 M TWD
Jan 1, 2019
360.99 M TWD
Jan 1, 2020
737.84 M TWD
Jan 1, 2021
806.81 M TWD
Jan 1, 2022
727.59 M TWD
Jan 1, 2023
1.25 B TWD
Jan 1, 2024
391.86 M TWD
Jan 1, 2025
125.87 M TWD
The Bionet Current Assets history
YEARCurrent AssetsYoY
125.87 MTWD-67.88%
391.86 MTWD-68.68%
1.25 BTWD+71.98%
727.59 MTWD-9.82%
806.81 MTWD+9.35%
737.84 MTWD+104.39%
360.99 MTWD+4.55%
345.27 MTWD+31.49%
262.57 MTWD-67.35%
804.25 MTWD-0.85%
811.17 MTWD+52.30%
532.60 MTWD-46.11%
988.26 MTWD-3.74%
1.03 BTWD+4.25%
984.73 MTWD+62.43%
606.26 MTWD-2.46%
621.55 MTWD+12.67%
551.65 MTWD+72.05%
320.63 MTWD-12.10%
364.75 MTWD+69.72%
214.92 MTWD+29.86%
165.50 MTWD-16.56%
198.35 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

Current Assets of Bionet is 125.87 M TWD in 2025.

Current Assets of Bionet changed from 391.86 M TWD to 125.87 M TWD, representing a -67.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Bionet since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Bionet historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bionet

All Key Metrics — Bionet